Revenue Forecasting of Originator, Generic and OTC Medicines and Therapy Areas Including CNS, Cardiovascular and Cancer; Exploration of Regional Differences in Healthcare; Discussion of Domestic Manufacturers Including EMS, Hypermarcas and Aché, and International Drug Companies Including Sanofi, Novartis and Roche
Medicine Sales in Brazil – How to Find Trends, Opportunities and Forecasted Revenues Do you want to assess Brazil’s pharmaceutical market from 2016? If so, Visiongain’s new report gives you revenue forecasts, helping your research and analysis. That study’s purpose is to show opportunities, trends and sales predictions to 2026.
Brazil can satisfy expectations for wider healthcare coverage and rapid expansion of its pharma industry and market. With our updated study you explore business analysis, developments and opportunities for domestic and foreign companies.
Please read on to explore Brazilian medical sales and see how high that fast developing country’s revenues could go.
Trends and outlooks for that emerging healthcare market – what is possible? From 2016 patients, treatment providers and the pharmaceutical industry will benefit from progress in Brazilian healthcare. Discover in our study what the future holds – medical needs and potential revenues. Also find rankings of companies.
Our new analysis shows you revenue predictions from 2016 to 2026 at overall national and submarket levels. You discover the most lucrative parts of that country’s drug market, seeing opportunities to benefit patients, healthcare providers and pharma companies. Explore what the future holds for domestic producers and multinational pharma companies.
Forecasts and other data help you find where the money lies in Brazil’s medical sales To support our forecasting, our work shows you historical results, sales growth rates and market shares. In our 191 page report you gain 52 tables, 55 charts and interviews with representatives from BiocadBrazil Farmaceutica and Sandoz Brazil.
With our study, see how you could save time and avoid struggles to find data to help your research, analysis, plans and presentations. See, too, how you could help your influence, benefiting your reputation for commercial insight on Brazilian pharma.
The following sections show how our investigation helps your work.
Potential of Brazil’s drug sales – overall market and segment forecasts What is Brazil’s potential as a pharma market? In our analysis you discover overall revenues to 2026, with discussions. Our report also shows you individual sales predictions – from 2016 to 2026 – for three main submarkets: •Patented therapies – original brands of prescription drugs • Generic pharmaceuticals (generics) • OTC medicines – over-the-counter treatments.
The future looks promising for Brazilian pharmaceutical sales. That developing national market is growing at a faster rate than more-mature markets, and can continue to do so over the next ten years. See what is possible.
With our study also extend your knowledge of that country’s medical needs and pharma industry. In addition you explore forecasting for therapeutic applications, assessing demand and potential revenues.
Diseases and their treatment – what prospects for drugs and their sellers? Our new study also predicts revenues in Brazil for treating prominent diseases. See individual revenue forecasts to 2026 for six therapeutic categories: • Central nervous system (CNS) • Cardiovascular (CV) • Gastrointestinal and metabolic • Cancer treatments (oncology) • Infectious diseases – anti-infective agents (vaccines and antibiotics) • Therapies for other disorders (grouped analysis).
How fast will those submarkets expand? How high will their revenues go? With our report you assess opportunities and potentials, seeing what developments and sales are possible.
There you also investigate what stimulates and restrains sales of drugs.
Issues and events in Brazil – what affects drug developers, producers and sellers? Our study discusses forces affecting Brazil’s medical sales from 2016, including these influences: • Efforts of companies and public healthcare providers to serve patients’ needs • Strategies of domestic and foreign companies, including mergers and acquisitions (M&A), drug launches, sales ranking and Brazilian market share • Trends in demographics, economics and epidemiology – assess medical needs, including Zika virus infection • Wholesalers, distributors and retailers of medicines – the supply chain • Governmental policies – explore activities of ANVISA and SUS and other bodies – including the new drug price adjustment system, the RENAME reimbursement programme and ANVISA reform of patent protection.
With our study you also assess these influences, among others: • Efforts by regions to improve medical provision, better serving populations • Healthcare insurance – public and private – to improve access to medicines • Technologies – competitors’ research and development and manufacturing • Technology transfer and IP protection, including action against counterfeiting • Rising demand for biological drugs, including biosimilars • Brazil’s position in overall world, Latin American, BRIC nations and pharmerging countries’ pharmaceutical markets.
With our analysis you examine political, economic, social and technological questions, assessing commercial prospects. You also investigate strengths, weaknesses, opportunities and threats.
Explore what stimulates and restrains domestic and foreign pharmaceutical companies in Brazil, discovering what is possible from 2016 to 2026.
Analysis of top companies and their industry – what future sales are possible? What happens next? Our work predicts the Brazilian pharma market will reach $31.1bn in 2020 – with strong expansion from 2016 to 2026. See what is possible.
In our report you discover what causes that sales growth and why Brazil attracts and develops pharma business. There you explore activities of 10 leading domestic companies and other firms, including these organisations: • EMS • Hypermarcas • Aché • Eurofarma • Cristália • Libbs • União Química.
You also assess 10 multinational – big pharma – organisations and other foreign players operating there, including these corporations: • Sanofi • Novartis • Roche • Pfizer • Takeda • Bayer • Merck & Co.
You also see interviews with BiocadBrazil Farmaceutica and Sandoz Brazil. Discover the efforts of pharma specialists, including firms making biopharmaceuticals. From 2016 many firms stand to gain.
Leading generic and biosimilar drug developers, producers and sellers In our report you assess other international manufacturers and marketers of drugs for Brazil, including generics and biosimilars: • Teva Pharmaceutical Industries • Mylan • Actavis • Daiichi Sankyo • Glenmark • Valeant • Strides Arcolab • Biocon.
Pharma industry leaders and specialty companies will expand their operations and sales there. Explore what is possible in Brazil and see how you could benefit.
5 ways Brazilian Pharmaceutical Market Outlook 2016-2026 helps your work In these five main ways, our investigation gives knowledge to benefit your research, analyses and decisions: • Brazil’s overall pharma revenues from 2016 – discover that leading developing country’s prospects for medical investments, marketing and sales • Submarkets’ revenues to 2026 – investigate 9 segments at national level, finding product groups and therapeutic needs with highest potential revenues • Prospects for domestic and foreign drug developers, producers and sellers – explore portfolios, R&D, product approvals, collaborations, M&A and outlooks • Opinion and news from companies – see views to help you stay ahead in knowledge, including two interviews • Analysis of what stimulates and restrains Brazil’s market for human medicines – assess challenges and strengths there, helping you compete and gain advantages.
That study, by our in-house analysts in the UK, gives data to benefit your work. Our survey shows information you find nowhere else, helping you stay ahead.
Independent analysis showing you the potential of Brazil’s pharma sales Our report gives analysis showing you the most promising opportunities. Discover progress and possibilities for pharmaceutical sales in Brazil.
Through choosing our study, see how you could save time and effort, also benefiting your authority and reputation for commercial insight.
Our investigation is for everyone analysing rising and emerging pharma markets. Brazil holds great commercial potential – our study shows you trends, forecasts and discussions to help you stay ahead in knowledge. So avoid missing out – please get our new report here now.
Visiongain is a trading partner with the US Federal Government CCR Ref number: KD4R6
1. Report Overview 1.1 Brazil: Pharmaceutical Market Overview 1.2 Brazilian Pharmaceutical Market Segmentation 1.3 Why You Should Read This Report 1.4 How This Report Delivers 1.5 Main Questions Answered by This Survey 1.6 Who is Our Report For? 1.7 Research and Analysis Methods 1.8 Frequently Asked Questions (FAQs) 1.9 Some Associated Reports 1.10 About Visiongain
2. Introduction to the Brazilian Pharmaceutical Market 2.1 The Brazilian Pharmaceutical Market Overview 2.2 Generics Segment Continues to Grow in Importance 2.3 CNS – The Largest Therapeutic Area in 2015 2.4 Four Domestic Companies in the Top Ten in 2015
3. The Significance of the Brazilian Market 3.1 Brazilian Economy is the Ninth Largest in the World 3.2 Brazil is the Eighth Largest Pharmaceutical Market 3.3 Brazil is the Largest Market in Latin America 3.4 Brazil Qualifies as a ‘Pharmerging’ Country and one of the BRIC Markets
4. Organisation of the Brazilian Pharmaceutical Market 4.1 ANVISA – Brazil’s Equivalent of the FDA 4.2 Other Influential Organisations 4.3 SUS – One of the World’s Largest Public Health Systems 4.4 Private Healthcare Accessed by 25% of the Population 4.5 Private Insurance Market Growing but Costs are Rising 4.6 New Drug Price Adjustment System Introduced 4.7 RENAME Drug Reimbursement System and the Farmácia Popular 4.8 Extensive Network of Pharmacies in Brazil 4.9 Wholesale and Retail Sectors Undergoing Consolidation 4.10 Panpharma is the Top Wholesale Distributor 4.11 Profarma is the Largest Mixed Distributor 4.12 Raia Drogasil is the Leader in the Retail Sector 4.13 Spending on Marketing Approaches $5bn
5. Major Differences in Healthcare Between Regions 5.1 Size and Prosperity of Different Regions 5.2 South-East is the Richest and Most Populous Region 5.3 South Has the Second Highest GDP 5.4 North-East Has the Second Highest Pharmaceutical Market Share 5.5 North is the Largest and Poorest Region 5.6 Mid-West is a Landlocked Region Housing the Nation’s Capital
6. Product Segments in the Brazilian Pharmaceutical Market 2016-2026 6.1 Forecasts for the Originator, Generic and OTC Segments 2015-2026 6.2 Originator Segment Will be Overtaken by Generics 6.2.1 Product Development Partnerships to Reduce Costs 6.2.2 Originator Drugs Threatened by 35% Cheaper Generics 6.3 Generics Drug Segment Forecast 2015-2026 – Continued Rapid Growth 6.3.1 Rapid Expansion of Generic Segment 6.3.2 Generic Companies Aiming for 45% Market Share 6.3.3 Similares Drugs Face Same Pricing Rules as Generics 6.3.4 Counterfeit Drugs Account for 20% of the Market 6.3.5 National Drug Security System to Tackle Counterfeit Drugs 6.3.6 Challenges for the Brazilian Generics Market 6.4 Brazilian Biologics Market 6.4.1 Biosimilars Market to Double in Size by 2017 6.4.2 BiocadBrazil Brings More Biosimilars to Brazil 6.5 OTC Drug Segment Forecast 2015-2026 6.5.1 Analgesics and Multivitamins Favoured by Brazilians 6.5.2 One Sixth of Population Buy Multivitamins 6.5.3 Restrictions on OTC Products Reversed 6.5.4 Consumer Health Treatments Remain Prominent in the Market
7. Therapeutic Areas of the Brazilian Market 2015-2026 7.1 Forecasts for CNS, Cardiovascular, Gastrointestinal/Metabolic, Oncology, Infectious Diseases and Other Therapeutic Areas, 2015-2016 7.2 The Rise of Non-Communicable Diseases 7.3 Market Forecast for CNS Conditions 2015-2026 7.3.1 CNS Conditions Currently the Largest Therapeutic Area 7.3.2 Domestic Companies Target Generic and OTC CNS Products 7.3.3 Foreign Companies Target Analgesics Market 7.3.4 One Fifth of Brazilians Have Suffered Depression 7.3.5 CNS Conditions: Drivers and Restraints 7.4 Market Forecast for Cardiovascular Therapeutic Area, 2015-2026 7.4.1 Rate of Cardiovascular Disease Expected to Triple 7.4.2 Almost One Quarter of the Population are Hypertensive 7.4.3 Statin Revenues Decline with Loss of Patent Protection 7.4.4 Domestic and International Companies Compete in CVS 7.4.5 Cardiovascular Opportunities and Challenges 7.5 Market Forecast for Gastrointestinal/Metabolic Therapeutic Area, 2015-2026 7.5.1 High Prevalence of Diabetes and GI Conditions 7.5.2 Low Awareness of Diabetes Amongst Population 7.5.3 Drive for Domestic Production of Insulin 7.5.4 EMS’s Generic Esomeprazole an Important Addition 7.5.5 Capturing the Gastrointestinal/Metabolic Disease Opportunity 7.6 Market Forecast for Oncology Therapeutic Area, 2015-2026 7.6.1 Cancer Treatment to Become the Leading Therapeutic Area 7.6.2 Increased Coverage of Cancer Care by Private Health Insurance Providers 7.6.3 What are the Commonest Cancers in Brazil? 7.6.4 Biosimilars Will Help Widen Access to Cancer Drugs 7.6.5 Cristália and Libbs Amongst Leading Oncology Companies 7.6.6 Promising Potential of the Oncology Therapeutic Area 7.7 Market Forecast for Infectious Diseases Therapeutic Area, 2015-2026 7.7.1 Vaccines and Antibiotics Lead Therapeutic Area 7.7.2 Brazil Increasingly Manufacturing its Own Vaccines 7.7.3 First Vaccination Programme Against Dengue Fever 7.7.4 Free Access to HIV Care Despite Concerns About Patent Protection 7.7.5 Chagas Disease and Other Tropical Infections 7.7.6 Long-Term Threat From Zika Virus Epidemic 7.7.7 Importance of Infectious Diseases Compared to Chronic Diseases 7.8 Market Forecast for Other Therapeutic Areas, 2015-2026
8. Domestic Companies in the Brazilian Market 8.1 The Top Ten Domestic Pharmaceutical Companies in 2015 8.2 Multinational Companies Still Own the Majority of the Market 8.3 Domestic Sector Actively Encouraged by Government 8.4 Domestic Firms Control 70% of Generics Market 8.5 EMS: Brazil’s Leading Pharmaceutical Company 8.5.1 Separate Divisions for Different Drug Categories 8.5.2 Full Production and R&D Capability 8.5.3 Legrand and Germed are Key Subsidiaries 8.5.4 Targeted Expansion Overseas 8.6 Hypermarcas: Market Leader in OTC and Branded Generics 8.6.1 Neo Quimica: Ranked Third in the Generics Segment 8.6.2 Subsidiaries Include Mantecorp and Brainfarma 8.7 Medley: Generics Company Owned by Sanofi 8.8 Aché: A Major Acquisition Target in Brazil 8.8.1 Anti-Inflammatory Acheflan Was First Drug Developed in Brazil 8.8.2 Involvement of Aché in Acquisitions Process 8.8.3 Part of Bionovis Collaboration 8.9 Eurofarma: Fifth Largest Domestic Company with Plans to Cover 90% of Latin America 8.9.1 Policy to Make Acquisitions in Latin America 8.10 Teuto Operates Largest Pharmaceutical Complex in Latin America 8.10.1 Melcon Partnership and Other Growth Strategies for Teuto 8.11 Biolab Farmaceutica Leads Cardiology Drugs Market 8.11.1 Partnering With German and Indian Companies 8.11.2 Current Pipeline and Product Launches 8.12 Cristalia: Largest Producer of Anaesthetics in Latin America 8.12.1 Approval from ANVISA to Produce Biosimilar Drugs 8.12.2 Leader in API Manufacturing 8.12.3 Involved in One Third of all PDPs 8.13 Libbs: Key Player in Cancer Treatment 8.13.1 Libbs Secures $106m in Funding from BNDES for New Biotechnology Facility 8.14 União Quimica: Huge Annual Production Capacity 8.14.1 Agreement with Novartis and Possible Public Offering in 2015 8.15 Other Domestic Players Include Laboratório Daudt Oliveira and Hebron 8.16 Biosimilar Collaborations 8.16.1 Bionovis: Conglomerate Developing 8 Biosimilars 8.16.2 Orygen: Conglomerate Aiming to Develop 7 Biologics 8.16.3 Other Biotech Players Include Biomm and Innova 8.16.4 Fiocruz: At the Heart of Multiple PDPs 8.16.5 ANVISA Reform of Brazilian Patent System
9. Multinational Companies in the Brazilian Market 9.1 The Top Ten Multinational Pharmaceutical Companies in Brazil, 2015 9.2 Notable M&A Activity 9.3 Sanofi: Medley Purchase Makes French Giant the Outright Leader 9.3.1 Group Companies Include Sanofi Pasteur and Genzyme 9.3.2 Inventory Mishandling and Dip in 2013 Results 9.4 Novartis: Only Multinational to Produce APIs in Brazil 9.4.1 PDPs and a New $342m Biotechnology Facility in the North East 9.4.2 Pricing and Reimbursement Solutions to Bring Costlier Drugs to Brazil 9.4.3 Investment in Expansion Plans 9.5 Roche: No Regrets About Staying in Brazil 9.5.1 Oncology Opportunity and Herceptin Pricing 9.6 Merck & Co. – Long-Standing Presence in the Brazilian Market 9.6.1 Five Factories and Five Broad Therapeutic Areas 9.6.2 Gardasil Added to SUS in 2013 9.6.3 Joint Venture with Eurofarma and Cristalia 9.7 Pfizer: Pursuing Strategy to Acquire Domestic Manufacturers 9.7.1 Portfolio Ranges from Orphan Biologics to Multivitamins 9.8 Takeda: Expanding its Brazilian Business 9.8.1 Acquisitions of Nycomed and Multilab 9.9 Bayer: Brazil is its Fifth Largest Market 9.9.1 OTC is a Major Focus in Brazil 9.10 AstraZeneca Targets Latin America 9.10.1 Struggling with Loss of Exclusivity and Patent Infringement 9.11 Boehringer Ingelheim: Pain, Cardiovascular and Respiratory Drugs Bolster Strong National Portfolio 9.11.1 Looking to Acquire OTC Brands 9.11.2 Technology Transfer Deal for Parkinson’s Disease 9.12 Merck KGaA Signed PDP with Bionovis for 8 Biosimilars 9.12.1 Two Divisions and Multiple Therapeutic Fields 9.13 Other Notable Multinationals in Brazil 9.13.1 GSK: Vaccines and Technology Transfer Opportunities 9.13.2 Abbott: Humira to Face Biosimilar Challenge in Brazil? 9.13.3 Abbott: Generics and Diagnostics-Led Growth Strategy 9.13.4 Eli Lilly: Investing in Upgrading Pharmaceutical Packaging Facility 9.13.5 Bristol-Myers Squibb: Divesting its Brazilian OTC Portfolio Rights 9.13.6 Baxter Entering Haemophilia Market Via Technology Transfer 9.13.7 Johnson & Johnson: Focusing on Consumer Health and Commodities 9.13.8 BiocadBrazil Farmaceutica 9.13.9 Amgen Signals Brazilian Intent with Bergamo Acquisition 9.13.10 Gilead, Novo Nordisk, Biogen, UCB and Meizler 9.13.11 Other Top Japanese Companies Trail Behind Takeda in Brazil 9.14 Will Multinational Generics Leaders Compete in Brazil? 9.14.1 Teva Targets Brazil 9.14.2 Mylan Acquires Agila to Boost Brazilian Strategy 9.14.3 Actavis May Target Brazil 9.14.4 Ranbaxy and Daiichi Sankyo 9.14.5 Torrent, Glenmark, Strides Arcolab and Biocon Looking to Brazil 9.14.6 Valeant: M&A Drive Into the Market 9.15 Brazil as a Pharmaceutical Research Destination
10. Qualitative Analysis of the Brazilian Pharmaceutical Market, 2016 10.1 Strengths, Weaknesses, Opportunities and Threats (SWOT) Analysis 10.1.1 A Crucial Market for the Pharmaceutical Industry 10.1.2 Government Regulation Remains an Issue 10.1.3 One of the Highest Pharmaceutical Tax Rates in the World 10.1.4 Room to Expand in Therapeutic Areas and Geographic Regions 10.1.5 Technology Transfer Uncertainties, IP Protection Doubts and Counterfeiting Issues 10.2 Social, Technological, Economic and Political (STEP) Analysis 10.2.1 Large and Ageing Population Eager to Buy Medicines 10.2.2 Shortcomings of Brazil’s Healthcare System 10.2.3 Government Aims for Greater Self-Sufficiency in Biotechnology and Health IT 10.2.4 Can Economic Growth Keep Pace with Healthcare Costs? 10.2.5 Political Environment Acts as Decisive Influence on the Market 10.2.6 Will BREXIT Affect Free Trade Negotiations with the EU?
11. Research Interviews 11.1 Interview With Vitor Zani, Business Development Coordinator, BiocadBrazil Farmaceutica 11.1.1 On Gaining Access to the Brazilian Market 11.1.2 Factors That Differentiate Brazil From Other Markets 11.1.3 The Brazilian Generics and Biosimilars Market and Biocad’s Progress with Biosimilars 11.1.4 Biocad’s Brazilian Pipeline, its Progress in 2014 and its Prospects for the Future 11.1.5 Development of the Brazilian Pharmaceutical Market 2015-2025; Drivers for Growth and Opportunity in the North East 11.1.6 Effect of the 2014 World Cup on the Brazilian Pharmaceutical Market and How the 2016 Olympics Will Compare 11.1.7 Strengths and Weaknesses of the Brazilian Pharmaceutical Market and Whether the Weaknesses Will Improve in Coming Years 11.2 Interview with André Brazay, President of Sandoz Brazil 11.2.1 Impact of Current Political and Economic Situation 11.2.2 Challenges faced by Domestic Companies 11.2.3 How Generics Market in Brazil Differs from Other Countries 11.2.4 Importance of Biosimilars in Brazil 11.2.5 Factors for an Overseas Investor to Consider 11.2.6 Future Challenges for the Market in Brazil
12. Conclusions from Our Research and Analysis 12.1 Growth of Brazil’s Pharmaceutical Market Will Outstrip That of More Developed Countries 12.2 Generics Will be Major Driver of Growth 12.3 Technology Transfer Boosts Domestic Production of Originator Drugs 12.4 Generics Market Provides Alternative Option for Multinationals 12.5 Oncology is Leading Therapeutic and Commercial Opportunity 12.6 Concluding Comments
List of Tables Table 1.1 Sample Table: Brazilian Pharmaceutical Market Breakdown Table 1.2 Currency Exchange Rates: Average Historic Exchange Rate to USD for 2014 and 2015 Table 2.1 Brazilian Pharmaceutical Market: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026 Table 2.2 Brazilian Pharmaceutical Market by Segment: Revenue ($bn) and Market Share (%), 2015 Table 2.3 Brazilian Pharmaceutical Market by Therapeutic Area: Revenue ($bn) and Market Share (%), 2015 Table 2.4 Brazilian Pharmaceutical Market: Top Ten Companies - Revenue ($bn) and Market Share (%), 2015 Table 3.1 World’s Largest Pharmaceutical Markets, Revenue ($bn) and Market Share (%), 2015 Table 3.2 Top Latin American Pharmaceutical Markets: Revenue ($bn) and Market Share (%), 2015 Table 3.3 Pharmerging Countries Table 4.1 Members of FenaSaúde (in Portuguese, with English in Brackets), 2016 Table 6.1 Originator Drug, Generic Drug and OTC Drug Segments Forecast: Revenue ($bn) and Market Share (%), 2015-2026 Table 6.2 Originator Drug, Generic Drug and OTC Drug Segments: Revenue ($bn) and Market Share (%), 2021 Table 6.3 Originator Drug, Generic Drug and OTC Drug Segments: Revenue ($bn) and Market Share (%), 2026 Table 6.4 Originator Drug, Generic Drug and OTC Drug Segments: Revenue Forecasts ($bn), 2015-2026 Table 6.5 Originator Drug Segment: Revenue Forecasts ($bn), 2015-2026 Table 6.6 Selected Technology Transfer Agreements in Brazil 1985-2013 Table 6.7 Generic Drug Segment: Revenue Forecasts ($bn), 2015-2026 Table 6.8 OTC Drug Segment: Revenue Forecasts ($bn), 2015-2026 Table 7.1 Brazilian Pharmaceutical Market – Therapeutic Areas: Revenue ($bn) and Market Share (%), 2015-2026 Table 7.2 Brazilian Pharmaceutical Market by Therapeutic Area: Revenue ($bn) and Market Share (%), 2021 Table 7.3 Brazilian Pharmaceutical Market by Therapeutic Area: Revenue ($bn) and Market Share (%), 2026 Table 7.4 CNS Therapeutic Area: Revenue ($bn) and Market Share (%), 2015-2026 Table 7.5 Cardiovascular Therapeutic Area: Revenue ($bn) and Market Share (%), 2015-2026 Table 7.6 Gastrointestinal/Metabolic Therapeutic Area: Revenue ($bn) and Market Share (%), 2015-2026 Table 7.7 Oncology Therapeutic Area: Revenue ($bn) and Market Share (%), 2015-2026 Table 7.8 Infectious Diseases Therapeutic Area: Revenue ($bn) and Market Share (%), 2015-2026 Table 7.9 Other Therapeutic Areas: Revenue ($bn) and Market Share (%), 2015-2026 Table 8.1 Top Ten Domestic Pharmaceutical Companies in Brazil: Revenue ($bn) and Market Share (%), 2015 Table 8.2 EMS Overview Table 8.3 Hypermarcas Overview Table 8.4 Medley Overview Table 8.5 Aché Overview Table 8.6 Eurofarma Overview Table 8.7 Teuto Overview Table 8.8 Biolab Farmacêutica Overview Table 8.9 Biolab Farmacêutica Pipeline, 2015 Table 8.10 Cristalia Overview Table 8.11 Libbs Overview Table 8.12 União Química Overview Table 9.1 Leading Multinational Companies in the Brazilian Market: Revenues ($bn), Market Shares (%), 2015 Table 9.2 Selected Multinational M&A Activity in the Brazilian Market, 2009-2012 Table 9.3 Sanofi Overview Table 9.4 Novartis Overview Table 9.5 Roche Overview Table 9.6 Merck & Co. Overview Table 9.7 Pfizer Overview Table 9.8 Takeda Overview Table 9.9 Bayer Overview Table 9.10 AstraZeneca Overview Table 9.11 Boehringer Ingelheim Overview Table 9.12 Merck KGaA Overview Table 10.1 Brazilian Pharmaceutical Market: Strengths and Weaknesses, 2016 Table 10.2 Brazilian Pharmaceutical Market: Opportunities and Threats, 2016 Table 10.3 Brazilian Pharmaceutical Market: STEP Analysis, 2016
List of Figures Figure 1.1 Product Segments of Brazilian Pharmaceutical Market Figure 1.2 Main Therapeutic Areas Within the Brazilian Pharmaceutical Market Figure 2.1 Brazilian Pharmaceutical Market: Revenue ($bn) 2015-2026 Figure 2.2 Brazilian Pharmaceutical Market by Segment: Market Share (%), 2015 Figure 2.3 Brazilian Pharmaceutical Market by Therapeutic Area: Market Share (%), 2015 Figure 2.4 Brazilian Pharmaceutical Market: Top Ten Companies – Market Share (%), 2015 Figure 3.1 Top Ten Global Economies, 2015 Figure 3.2 Top Ten Global Economies, 2030 Figure 3.3 World’s Largest Pharmaceutical Markets by Market Share (%), 2015 Figure 3.4 Top Latin American Pharmaceutical Markets: Market Share (%), 2015 Figure 3.5 BRIC Countries Pharmaceutical Market Revenue ($bn), 2015 Figure 4.1 Public Healthcare Versus Private Healthcare: Market Share (%), 2015 Figure 5.1 Doctors per 1,000 Inhabitants by Brazilian Region, 2013 Figure 5.2 Brazil: Regional Population Shares (%), 2013 Figure 5.3 Brazilian Pharmaceutical Market Shares (%) by Region, 2012 Figure 5.4 Brazilian GDP Shares (%) by Region, 2013 Figure 6.1 Originator Drug, Generic Drug and OTC Drug Segments: Market Share (%), 2021 Figure 6.2 Originator Drug, Generic Drug and OTC Drug Segments: Market Share (%), 2026 Figure 6.3 Originator Drug, Generic Drug and OTC Drug Segments: Revenue Forecasts ($bn), 2015-2026 Figure 6.4 Originator Drug, Generic Drug and OTC Drug Segments: Revenue ($bn), 2015, 2021, 2026 Figure 6.5 Originator Drug Segment: Revenue ($bn) 2015-2026 Figure 6.6 Drivers and Restraints for Patented Pharmaceuticals, 2016 Figure 6.7 Generic Drug Segment: Revenue ($bn) 2015-2026 Figure 6.8 Drivers and Restraints for Generic Drugs, 2016 Figure 6.9 Brazilian Biologics Market Breakdown: Revenue ($bn) and Market Share (%), 2015 Figure 6.10 Brazilian Biologics Market Breakdown: Revenue ($bn), 2015,2021, 2026 Figure 6.11 OTC Drug Segment: Revenue ($bn) 2015-2026 Figure 6.12 Drivers and Restraints for OTC Drugs, 2016 Figure 7.1 Brazilian Pharmaceutical Market by Therapeutic Area: Market Share (%), 2021 Figure 7.2 Brazilian Pharmaceutical Market by Therapeutic Area: Market Share (%), 2026 Figure 7.3 Brazilian Pharmaceutical Market by Therapeutic Area: Revenue Forecasts ($bn), 2015-2026 Figure 7.4 Brazilian Pharmaceutical Market by Therapeutic Area: Revenue ($bn), 2015, 2021, 2026 Figure 7.5 CNS Therapeutic Area: Revenue ($bn), 2015-2026 Figure 7.6 Drivers and Restraints for CNS Conditions, 2016 Figure 7.7 Cardiovascular Therapeutic Area: Revenue ($bn), 2015-2026 Figure 7.8 Drivers and Restraints for the Cardiovascular Therapy Area, 2016 Figure 7.9 Gastrointestinal/Metabolic Therapeutic Area: Revenue ($bn), 2015-2026 Figure 7.10 Drivers and Restraints for Gastrointestinal/Metabolic Therapy Area, 2016 Figure 7.11 Oncology Therapeutic Area: Revenue ($bn) 2015-2026 Figure 7.12 Estimated Cancer Incidence for Males in Brazil, 2016 Figure 7.13 Estimated Cancer Incidence for Females in Brazil, 2016 Figure 7.14 Drivers and Restraints for the Oncology Therapeutic Area, 2016 Figure 7.15 Infectious Diseases Therapeutic Area: Revenue ($bn), 2015-2026 Figure 7.16 Drivers and Restraints for the Infectious Disease Therapeutic Area, 2016 Figure 7.17 Other Therapeutic Areas: Revenue ($bn), 2015-2026 Figure 8.1 Top Ten Domestic Pharmaceutical Companies in Brazil: Market Share (%), 2015 Figure 8.2 Aché Product Portfolio Breakdown (%), 2013 Figure 9.1 Leading Multinational Companies in the Brazilian Market: Market Shares (%), 2015 Figure 12.1 Brazilian Pharmaceutical Market: Overall Revenue ($bn), 2015-2021 Figure 12.2 Brazilian Pharmaceutical Market: Overall Revenue ($bn), 2021-2026 Figure 12.3 Brazilian Pharmaceutical Market by Segment: Revenue ($bn), 2015-2021 Figure 12.4 Brazilian Pharmaceutical Market by Segment: Revenue ($bn), 2021-2026 Figure 12.5 Top Ten Companies in the Brazilian Pharmaceutical Market: Revenue ($bn), 2015 Figure 12.6 Brazilian Pharmaceutical Market Therapeutic Area Breakdown: Revenue ($bn), 2015-2021 Figure 12.7 Brazilian Pharmaceutical Market Therapeutic Area Breakdown: Revenue ($bn), 2021-2026
Abbott Laboratories Aché Laboratórios Farmacêuticos S.A Actavis PLC Agência Nacional de Saúde Suplementar (ANS) Agência Nacional de Vigilância Sanitária (ANVISA) Agila Specialties Private Ltd Allianz Saúde Alteogen Inc AMB (Brazilian Medical Association) American Diabetes Association ADA) AmerisourceBergen Corporation (ABC) Amgen Inc Antaris Consulting Associação Brasileira das Redes de Farmácias e Drogarias (ABRAFARMA) Associação Brasileira de Reabilitação de Coluna (Brazilian Association of Back Rehabilitation) Associação da Industria Farmacêutica de Pesquisa (Interfarma) Associação Nacional de Assistencia ao Diabetico (ANAD) Astellas Pharma Inc AstraZeneca PLC Athos Farma SA Axis Biotec Brasil Baxter International Inc Bayer AG Bergamo Ltda Beth Israel Hospital Bill & Melinda Gates Foundation Billi Farmacêutica Biocad BiocadBrazil Farmaceutica Biocon Limited Biolab Emcure Farmaceutica Comercial Ltda Biolab Farmaceutica Bio-Manguinhos (Instituta de Tecnologia em Imunobiologicos) Biomm SA Bionovis SA Biovail Corporation Boehringer Ingelheim GmbH Boiron Brainfarma Indústria Química e Farmacêutica BrasilPharma Brazil Produtos Roche Químicos e Farmacêuticos Brazilian Institute of Tax Planning Brazilian National Bank for Economic and Social Development (BNDES) Brazilian National Institute of Social Security (INSS) Bristol-Myers Squibb (BMS) British Medical Journal (BMJ) BTG Pactual Bunker Industria Farmaceutica Butantan Institute Câmara de Regulação do Mercado de Medicamentos (CMED) Care Plus Medicina Assistencial S/S Ltda Ceitec SA Celesio AG Centre for Economics and Business Research (CEBR) Chemo Group Claris Lifesciences Ltd Conselho Federal de Farmácia Conselho Federal de Medicina (CFM) Corporacion Infarmasa SA Cosmed Industria de Cosmeticos e Medicamentos Cristália CVS Pharmacy Daiichi Sankyo Delta Dimed SA Distribuidora Farmacêutica Panarello Ltda DM Industria Farmacêutica Ltda Drogaria Sao Paulo Drogarias DPSP SA Drogarias Farmais Drogarias Pacheco Drogarias Tamoio Drogasil SA Eisai Co Ltd Eli Lilly & Co Emcure Pharmaceuticals Ltd Empresas Andromaco EMS Eurofarma Eurofarma Argentine Eurofarma Chile Eurofarma Uruguay European Medicines Agency (EMA) Everis Group F. Hoffmann-La Roche AG Farmácia Ben Farmácia Popular Farmacias Mais Econômica Farmácias Guararapes Farmalife Farmanguinhos (Instituto de Tecnologia em Farmacos) Farmindustria SA Federação Nacional de Saúde Suplementar (FenaSaúde) Federal Court of Rio de Janeiro Food and Drug Administration (FDA) Forest Laboratories Inc Fundação Oswaldo Cruz (FioCruz) Fundação Ezequiel Dias (Funed) Genzyme Corporation Germed Pharma Gilead Sciences Inc GlaxoSmithKline PLC (GSK) Glenmark Pharmaceuticals Golden Cross Government of Brazil Grünenthal Group Grupo Amil Saúde Grupo Bradesco Saúde Grupo Cimed Grupo Notre Dame Intermédica Saúde Grupo SulAmérica Saúde Hapvida Assistência Médica Health Canada Health Network Formation and Quality Improvement Project (QualiSUS) Hebron Hemobrás Horizon Pharma PLC Hospital das Clínicas, São Paulo Hospital Israelita Albert Einstein Hospital Santa Catarina Hypermarcas IMA Laboratories Indar Institute Indian Council of Medical Research Innova Pharma Institute for Health Insurance (IESS) Instituto Brasileiro de Geografia e Estatística (IBGE) Instituto de Estudos de Saúde Suplementar (IESS) Instituto de Tecnologia do Paraná (TECPAR) Instituto Terapeutico Delta Instituto Vital Brazil Janssen Johnson & Johnson Kantar Health Kenya Medical Research Institute Laboratório Daudt Oliveira Laboratório Farmacȇutico do Estado de Pernambuco (LAFEPE) Laboratório Prata Laboratório Sanobiol Laboratório Teuto Laboratorio Volta Laboratório Tiaraju Laboratórios Gautier Laboratórios Klinger Do Brasil Laboratorios Laprin S.A Lazard Legrand Pharma Industria Farmaceutica Ltda Libbs Biotec Libbs Farmacêutica Ltda Luper Indústria Farmacêutica mAbxience Mantecorp Quimica Industria e Farmaceutica Ltda Médecins sans Frontières (MSF) Medley Farmacêutica Meizler Biopharma SA Melcon Indústria Farmacêutica SA Merck & Co., Inc Merck KGaA Merck Serono Mercosur Merial Merz Pharma GmbH & Co. KGaA Metlife Exclusivamente Odontológicos Metropolitan Life Insurance Company Minas Gerais State Department of Health Ministry of Health of Malaysia Ministry of Health, Brazil Moksha8 Multilab Industria e Comerci de Produtos Farma Mundipharma International Ltd Mylan NV National Institutes of Health Nature's Plus Farmacêutica Ltda NeoQuimica Nortis Farmaceutica Ltda Novartis AG Novartis Biociências Novo Nordisk A/S Nycomed OdontoPrev Omint Serviços de Saúde Oncoprod Optimer Pharmaceuticals Inc Organisation for Economic Co-operation and Development (OECD) Orygen Biotecnologia Otsuka Pharmaceutical Co Ltd Pan American Health Organization Panpharma Pasteur Institute Pele Nova Biotecnologia SA Pfizer Inc PharmaPraxis Porto Seguro - Seguro Saúde Probiomed SA de CV Probiotica Laboratórios Ltda Procter and Gamble Co Profarma Profarma Specialty SA Pró-Genéricos (the Brazilian Association of Generic Drug Industries) Protalix BioTherapeutics Inc Quesada Farmacêutica SA Quintiles Inc Raia Drogasil Raia SA Ranbaxy Laboratories Ltd Reckitt Benckiser Group PLC Roche Diagnostica Brasil Rosário Sabin Vaccine Institute Sandoz Brazil Sandoz do Brasil Indústria Farmacêutica Sanofi Sanofi Pasteur SA Sant’Ana S.A. Drogaria Farmácias Santa Cruz Distribuidora de Medicamentos São Paulo Stock Exchange Savicevic Participacoes SA SC Participações Empresariais Ltda Schwarz Pharma Serum Therapeutic Institute Shasun Pharmaceuticals Ltd Sinclair IS Pharma PLC Sindicato do Comércio Atacadista de Drogas, Medicamentos, Correlatos, Perfumarias, Cosmeticos e Artigos de Toucador no Estado de São Paulo (SINCAMESP) Sindusfarma Sistema Único de Saúde (SUS) State Pharmaceutical Laboratory of Pernambuco (LAFEPE) Strides Arcolab Sun Pharmaceutical Industries Ltd Supera Farma Laboratorios Takeda Pharmaceutical Company Ltd Telefônica Digital Teva Pharmaceutical Industries Ltd The Walgreen Company The Working Group on Intellectual Property of the Brazilian Network for the Integration of Peoples (GTPI/Rebrip TKS Farmacêutica Ltda Torrent Pharmaceuticals Ltd UCB Pharma SA UERJ (Universidade do Estado do Rio de Janeiro) União Química Farmacêutica Nacional SA UNICAMP (Universidade Estadual de Campinas) Unimed Seguros Saúde University of São Paulo University of Texas Valeant Pharmaceuticals International Inc Walter Reed Army Institute of Research Warc Watson Pharmaceuticals Inc Wockhardt Ltd World Bank World Health Organization (WHO) Yasuda Marítima Saúde Seguros SA Zydus Cadila
Download sample pages
Complete the form below to download your free sample pages for Brazilian Pharmaceutical Market Outlook 2016-2026
Download sample pages
Complete the form below to download your free sample pages for Brazilian Pharmaceutical Market Outlook 2016-2026
Visiongain’s reports are based on comprehensive primary and secondary research. Those studies provide global market forecasts (sales by drug and class, with sub-markets and leading nations covered) and analyses of market drivers and restraints (including SWOT analysis) and current pipeline developments. To find out more about our reports methodology, please email sara.peerun@visiongain.com
Win a Free Visiongain Pharma report – ‘Like’ our Pharma Facebook page with the link below and enter into our raffle to win a free, unlocked Visiongain report, choosing your relevant report from our reports selection.
The rising prevalence of oncological disorders, lung infections, rising demand for customised drugs coupled with new orphan diseases discoveries, are few of the major reasons responsible for development of pharmaceutical spray drying market.
Deviating from protocols raises the danger of missing or delaying data collection from current investigations. This highlights the growing importance of digital medicine, which is being aided by advancements in cloud, mobile, and IoT technology.
Visiongain Publishes Drug Discovery Informatics Market Report 2021-2031
High performance HPC and supercomputing technology have evolved substantially in China in the last decades, leading to extraordinary accomplishments. HPC-based and combined pharmaceutical chemical and computational biology computational discovery and design has become a significant technique in drug research and development and is sponsored financially by the Chinese government.
Visiongain Publishes Pharma Wholesale and Distribution Market Report 2021-2031
Many health-care organizations are seeing organic growth at levels that their supply networks were never designed to handle. Others are frantically attempting to integrate diverse technology and procedures as part of a consolidation effort.
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
